share_log

康弘药业(002773.SZ)：收到缅甸政府卫生部食品药品监督管理局《药品注册证书》

Chengdu Kanghong Pharmaceutical Group (002773.SZ) has received the Drug Registration Certificate from the Food and Drug Administration of the Ministry of Health of Myanmar.

Gelonghui Finance ·  Jun 18 07:34

On June 18th, Gelunhui learned that Chengdu Kanghong Biotechnology Co., Ltd., a wholly-owned subsidiary of Chengdu Kanghong Pharmaceutical Group, and China International Medical and Health Co., Ltd. (the exclusive registered dealer of the company in the Republic of the Union of Myanmar, referred to as "Myanmar"), recently received a drug registration certificate for Langmu (Conbercept Injection for Intravitreal Use) issued by the Food and Drug Administration of the Ministry of Health of the government of the Republic of the Union of Myanmar. Conbercept injection for intravitreal use is a type 1 biological innovative drug with complete independent intellectual property rights developed by Kanghong Biotechnology, a wholly-owned subsidiary of the company. The product can effectively bind with VEGF in blood vessels and tissues, block the signal transduction mediated by VEGF promoting the budding and growth of new blood vessels. The drug registration certificate issued by the Food and Drug Administration of the Ministry of Health of the government of the Republic of the Union of Myanmar this time marks that Langmu (Conbercept injection for intravitreal use) has obtained the qualification for access to the Myanmar market, which is significant for promoting the sales of the product for the treatment of wet age-related macular degeneration (nAMD) in the registered country.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment